The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
Publications
Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?
Annals of the rheumatic diseases. 2021;80(7):e120
de Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.
Cancer immunology research. 2019;7(1):6-11
Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors.
Autoimmunity reviews. 2018;17(6):610-616
Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation.
Annals of the New York Academy of Sciences. 2010;1183:222-36